Dose is a manufacturing and financing assumption as well as a clinical one: delivery volume and achievable titre bound it, and cost per dose follows from both. An independent, evidence-based assessment documents the dose and manufacturing economics the current data supports, rather than leaving that assumption unaddressed.
Part of Gene Therapy Consultancy's (GTC) work removing avoidable hurdles between promising early-stage science and a manufacturable program.
Genome-copy and cell-based thresholds that hold up in a 2D or 3D cell-culture model do not automatically translate into the in vivo dose a real tissue or lesion volume will require. That gap is where commercial-viability assumptions can be built on a bench result treated as a dosing number, without the boundary conditions made explicit.
An independent assessment makes that translation, and its limits, explicit: what the bench data does and does not support, and what would need to be true in vivo for the program to remain commercially viable at the dose actually required.
The assessment documents the commercial-viability picture your program can defend today, and the specific evidence gaps that stand between the current dataset and a defensible commercial case.
This assessment provides an independent commercial-viability read on your program's data. It does not replace a Contract Development and Manufacturing Organization (CDMO), a Contract Research Organization (CRO), a Qualified Person (QP), or qualified legal and regulatory counsel — and it is not a substitute for their scope of work.
Frequently asked questions about the commercial viability assessment
A brief, no-obligation conversation to see whether an independent commercial-viability assessment is the right next step for your program.
Book a Free Discovery Call